At the European Crohn’s and Colitis Organisation congress, Celltrion Healthcare shared positive safety and efficacy data on maintenance therapy including its infliximab biobetter allowing for subcutaneous administration, Remsima SC.
Celltrion Healthcare shared positive phase 3 safety and efficacy data regarding its infliximab biobetter, Remsima SC, as maintenance therapy in patients with inflammatory bowel disease (IBD) at the European Crohn’s and Colitis Organization congress.
The data come after the FDA accepted Celltrion’s biologics license application for Remsima SC in January 2023. Intravenous Remsima was approved by the FDA in April 2016 and launched on the US market in November 2016, where it is marketed as Inflectra through a commercialization agreement with Pfizer. It is 1 of 4 infliximab biosimilars approved in the United States.
“We believe that CT-P13 SC, if approved in the U.S., has the potential to become the next-generation innovative therapeutic for IBD given its favorable clinical results and convenient subcutaneous route of administration,” commented Kevin Byoung Seo Choi, senior vice president and head of marketing division at Celltrion Healthcare.
Biobetters are a class of follow-on biologic products that are intentionally altered to improve clinical effects, allow for more time in between doses, or enhance tolerability. Although many biobetters are developed as alterations to originator biologics, Remsima SC is unique in that it is a biobetter based on a biosimilar of Remicade (reference infliximab). Remsima SC (CT-P13) is the world first subcutaneous infliximab product, which can be a more convenient method of administration for patients than intravenous injection.
IBD is an umbrella term for Crohn disease (CD) and ulcerative colitis (UC). The LIBERTY-CD and LIBERTY-UC trials were randomized, placebo-controlled, double-blind analyses that measured Remsima SC (CT-P13 SC) through 54 weeks. In total, 343 patients with IBD were randomized to receive the biobetter or placebo.
In the CD study, at week 54, the clinical remission rate was greater in the biobetter arm than the placebo arm (62.3% vs 32.1%, respectively; P < .0001). In the UC analysis, 438 patients were randomized to either treatment arm. At week 54, the rate of clinical remission was also significantly greater in the biobetter arm than the placebo arm (43.2% vs 20.8%, respectively; P < .001). The safety profile was comparable between treatment arms in both studies.
“These latest findings add to the growing body of evidence that supports the SC formulation of infliximab as a convenient and effective solution for treating IBD….These results demonstrate that maintenance therapy with CT-P13 SC provides a robust clinical benefit, with the convenience of SC administration, for patients with moderately to severely active CD and UC,” presenting author Jean-Frédéric Colombel, MD, director of the Inflammatory Bowel Disease Center at the Icahn School of Medicine at Mount Sinai, said in a statement.
The new data are an update to older data from the phase 3 LIBERTY trial that were shared at the European Congress of Rheumatology’s annual meeting in June 2022.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
How Streamlining Development Can Save the US Biosimilar Industry
August 20th 2023On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, expanded on ways to make biosimilar development faster and cheaper without compromising on safety and efficacy and how these practices can ensure a sustainable market for the future.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.